B cell repertoire sequencing of HIV-1 pediatric elite-neutralizers identifies multiple broadly neutralizing antibody clonotypes.

B cell repertoire sequencing HIV-1 bnAbs children clonotypes elite-neutralizers

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 04 08 2023
accepted: 02 02 2024
medline: 4 3 2024
pubmed: 4 3 2024
entrez: 4 3 2024
Statut: epublish

Résumé

A limited subset of HIV-1 infected adult individuals typically after at least 2-3 years of chronic infection, develop broadly neutralizing antibodies (bnAbs), suggesting that highly conserved neutralizing epitopes on the HIV-1 envelope glycoprotein are difficult for B cell receptors to effectively target, during natural infection. Recent studies have shown the evolution of bnAbs in HIV-1 infected infants. We used bulk BCR sequencing (BCR-seq) to profile the B cell receptors from longitudinal samples (3 time points) collected from a rare pair of antiretroviralnaïve, HIV-1 infected pediatric monozygotic twins (AIIMS_329 and AIIMS_330) who displayed elite plasma neutralizing activity against HIV-1. BCR-seq of both twins revealed convergent antibody characteristics including V-gene use, CDRH3 lengths and somatic hypermutation (SHM). Further, antibody clonotypes with genetic features similar to highly potent bnAbs isolated from adults showed ongoing development in donor AIIMS_330 but not in AIIMS_329, corroborating our earlier findings based on plasma bnAbs responses. An increase in SHM was observed in sequences of the IgA isotype from AIIMS_330. This study suggests that children living with chronic HIV-1 can develop clonotypes of HIV-1 bnAbs against multiple envelope epitopes similar to those isolated from adults, highlighting that such B cells could be steered to elicit bnAbs responses through vaccines aimed to induce bnAbs against HIV-1 in a broad range of people including children.

Identifiants

pubmed: 38433846
doi: 10.3389/fimmu.2024.1272493
pmc: PMC10905035
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1272493

Informations de copyright

Copyright © 2024 Kumar, Bajpai, Joyce, Kabra, Lodha, Burton, Briney and Luthra.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Auteurs

Sanjeev Kumar (S)

Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, United States.
Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA, United States.
Center for Viral Systems Biology, The Scripps Research Institute, La Jolla, CA, United States.
International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, United States.

Prashant Bajpai (P)

International Centre for Genetic Engineering and Biotechnology (ICGEB)-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi, India.

Collin Joyce (C)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, United States.
Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA, United States.
Center for Viral Systems Biology, The Scripps Research Institute, La Jolla, CA, United States.
International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, United States.

Sushil Kumar Kabra (SK)

Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.

Rakesh Lodha (R)

Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.

Dennis R Burton (DR)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, United States.
Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA, United States.
Center for Viral Systems Biology, The Scripps Research Institute, La Jolla, CA, United States.
International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, United States.

Bryan Briney (B)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, United States.
Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA, United States.
Center for Viral Systems Biology, The Scripps Research Institute, La Jolla, CA, United States.
Multi-omics Vaccine Evaluation Consortium, The Scripps Research Institute, La Jolla, CA, United States.

Kalpana Luthra (K)

Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.

Classifications MeSH